Literature DB >> 15458402

Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy.

Kelly S Doran1, Victor Nizet.   

Abstract

The process of human infection by group B Streptococcus (GBS) is complex and multifactorial. While this bacterium has adapted well to asymptomatic colonization of adult humans, it remains a potentially devastating pathogen to susceptible infants. Advances in molecular techniques and refinement of in vitro and in vivo model systems have elucidated key elements of the pathogenic process, from initial attachment to the maternal vaginal epithelium to penetration of the newborn blood-brain barrier. Sequencing of two complete GBS genomes has provided additional context for interpretation of experimental data and comparison to other well-studied pathogens. Here we review recent discoveries regarding GBS virulence mechanisms, many of which are revealed or magnified by the unique circumstances of the birthing process and the deficiencies of neonatal immune defence. Appreciation of the formidable array of GBS virulence factors underscores why this bacterium remains at the forefront of neonatal pathogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458402     DOI: 10.1111/j.1365-2958.2004.04266.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  100 in total

1.  The neonatal group B streptococcal epidemic: lessons learned from studying associations.

Authors:  Michael P Sherman; Michael S Cooperstock
Journal:  Neonatology       Date:  2011-10-18       Impact factor: 4.035

2.  The 2-Cys peroxiredoxin alkyl hydroperoxide reductase c binds heme and participates in its intracellular availability in Streptococcus agalactiae.

Authors:  Delphine Lechardeur; Annabelle Fernandez; Bruno Robert; Philippe Gaudu; Patrick Trieu-Cuot; Gilles Lamberet; Alexandra Gruss
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

Review 3.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in Streptococcus agalactiae.

Authors:  Lakshmi Rajagopal; Anthony Vo; Aurelio Silvestroni; Craig E Rubens
Journal:  Mol Microbiol       Date:  2006-09-27       Impact factor: 3.501

5.  Sialylation of group B streptococcal capsular polysaccharide is mediated by cpsK and is required for optimal capsule polymerization and expression.

Authors:  D O Chaffin; L M Mentele; C E Rubens
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

6.  An IgG-like domain in the minor pilin GBS52 of Streptococcus agalactiae mediates lung epithelial cell adhesion.

Authors:  Vengadesan Krishnan; Andrew H Gaspar; Naiqing Ye; Anjali Mandlik; Hung Ton-That; Sthanam V L Narayana
Journal:  Structure       Date:  2007-08       Impact factor: 5.006

7.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

8.  Identification of Group B Streptococcus Capsule Type by Use of a Dual Phenotypic/Genotypic Assay.

Authors:  Areej Alhhazmi; Armaan Pandey; Gregory J Tyrrell
Journal:  J Clin Microbiol       Date:  2017-06-14       Impact factor: 5.948

9.  Threonine phosphorylation prevents promoter DNA binding of the Group B Streptococcus response regulator CovR.

Authors:  Wan-Jung Lin; Don Walthers; James E Connelly; Kellie Burnside; Kelsea A Jewell; Linda J Kenney; Lakshmi Rajagopal
Journal:  Mol Microbiol       Date:  2009-01-23       Impact factor: 3.501

10.  Variation in the group B Streptococcus CsrRS regulon and effects on pathogenicity.

Authors:  Sheng-Mei Jiang; Nadeeza Ishmael; Julie Dunning Hotopp; Manuela Puliti; Luciana Tissi; Nikhil Kumar; Michael J Cieslewicz; Hervé Tettelin; Michael R Wessels
Journal:  J Bacteriol       Date:  2008-01-18       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.